Analysis Halozyme Therapeutics, Inc. (0J2O)
6/4/2024
Analysis of Halozyme Therapeutics, Inc. (0J2O)
Halozyme Therapeutics, Inc. is a biotechnology company that focuses on developing and commercializing novel oncology therapies. The company's stock symbol is 0J2O.Looking at the recent data, we can see that the stock price has been showing an upward trend over the past few days. The RSI indicator is showing values above 50, indicating a bullish momentum. The MACD indicator is also positive, with the MACD line above the signal line, suggesting a potential buying opportunity.
The moving averages (SMA, EMA, WMA) are all trending upwards, further supporting the bullish outlook for the stock.
Overall, based on the technical indicators and recent price movements, it seems that Halozyme Therapeutics, Inc. may be in a good position for potential growth in the near future. However, as with any investment, it is important to conduct thorough research and consider other factors before making any trading decisions.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a range from $1.18 to $1.26. This shows growth compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a range from $1.33 to $1.51. This also indicates growth compared to the EPS of $1.35 from the same quarter a year ago.
3. For the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, with a range from $5.95 to $6.41. This reflects an increase compared to the EPS of $5.67 from the previous fiscal year.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a range from $5.92 to $7.31. This suggests further growth compared to the estimated EPS for the current fiscal year.
Overall, the analysts' estimates point towards a positive outlook with expected earnings growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with expected growth in both the quarterly and annual sales figures. The number of analysts providing estimates is consistent across the different time periods, indicating a stable level of interest in the company's financial performance.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.6%
- The next quarter growth rate is 5.1%
- The current quarter growth rate is 5.1%
- The next year growth rate is 9.7%
- The next 5 years compound annual growth rate (CAGR) is 9.7%
- The past 5 years compound annual growth rate (CAGR) is 20.1%
It can be observed that the company is expected to experience a significant increase in growth compared to the past 5 years, with a higher growth rate projected for the future. The next year and the next 5 years are expected to show a similar growth rate, indicating sustained growth over the medium term.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $275, and the average at $204.58. The current price of the security is $192.25, which is below the median and average forecasted prices. Investors should consider these forecasts along with other factors when making investment decisions.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided yet. The previous results from February 27, 2025, were related to the transfer agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at a specific time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and key financial figures include EBITDA, revenue, diluted EPS, gross profit, and net income.
Stock statistics show details such as short ratio, float shares, shares outstanding, and percentages held by insiders and institutions. Valuation metrics include PEG ratio, forward and trailing P/E ratios, enterprise value, price to book, price to sales, and market capitalization.
The stock price summary provides information on beta, moving averages, fifty-two week high and low, and the percentage change over the past year. Dividends and splits data include payout ratio, dividend dates, split dates, dividend rates, and yield information.
Overall, these data points offer a comprehensive overview of the company's financial health, stock performance, valuation, and dividend policy.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the past four fiscal years.
2. The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) has also shown a positive trend, indicating operational efficiency.
3. Net income has been growing consistently, reflecting the company's profitability.
4. Despite fluctuations in other income and expenses, the company has managed to maintain a strong financial performance.
5. The basic and diluted earnings per share (EPS) have remained relatively stable over the years.
6. The company has effectively managed its operating expenses in relation to its revenue growth.
7. The non-operating interest income and expenses have had a minor impact on the overall financial performance.
8. The number of basic and diluted shares outstanding has remained constant, indicating no significant dilution of shares.
9. The company's gross profit margin has been relatively stable, suggesting effective cost management strategies.
Overall, the financial data indicates a positive and consistent growth trajectory for the company over the past four fiscal years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments, machinery, and land improvements.
4. Total liabilities have also been increasing, but at a slower pace compared to assets, indicating a healthy financial position.
5. Shareholders' equity has shown a positive trend, with a notable increase in retained earnings.
6. The company has been managing its short-term and long-term debts effectively, with a good proportion of equity to liabilities.
7. Overall, the financial health of the company seems stable and improving over the years.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
MACD of 0J2O
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
